B Group, Inc.
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), B Group, Inc. reported 18 stock positions worth $163.6 million. Its top holding was Invesco QQQ TR at 34.4% of the portfolio, followed by Adma Biologics (ADMA, 24.0%) and Insmed (INSM, 14.8%).
- Most Recent 13F
- Q2 2026
- Location
- DALLAS, TX
- CIK
- 0002043476
- Portfolio Value
- $163.6M (Q4 2024)
- SEC Filing
- 0001420506-25-000436 ↗ filed Feb 14, 2025
Holdings Value
Holdings 18 stocks · $163.6M
| INVESCO QQQ TR | 34.37% | 110,000 | $56.2M | — |
| ADMA Adma Biologics Inc. | 23.98% | 2,287,542 | $39.2M | — |
| INSM Insmed Inc. | 14.77% | 350,000 | $24.2M | — |
| ZLAB Zai Lab Ltd.-ADR | 6.40% | 400,000 | $10.5M | — |
| IOVA Iovance Biotherapeutics Inc. | 4.49% | 992,000 | $7.3M | — |
| AKRO Akero Therapeutics Inc. | 4.42% | 260,000 | $7.2M | — |
| CLLS Cellectis - ADR | 3.39% | 3,081,501 | $5.5M | — |
| AURA Aura Biosciences Inc. | 2.37% | 472,576 | $3.9M | — |
| SGHT Sight Sciences Inc. | 1.40% | 629,370 | $2.3M | — |
| TSHA Taysha Gene Therapies Inc. | 1.02% | 965,556 | $1.7M | — |
| ULTRAGENYX PHARMACEUTICAL IN | 0.76% | 29,500 | $1.2M | — |
| SYRE Spyre Therapeutics Inc. | 0.71% | 50,000 | $1.2M | — |
| ASMB Assembly Biosciences Inc. | 0.49% | 50,651 | $799K | — |
| APGE Apogee Therapeutics Inc. | 0.42% | 15,000 | $680K | — |
| CORVUS PHARMACEUTICALS INC | 0.33% | 100,000 | $535K | — |
| BNTX Biontech SE-ADR | 0.24% | 3,500 | $399K | — |
| ORKA Oruka Therapeutics Inc. | 0.24% | 20,000 | $388K | — |
| RARE Ultragenyx Pharmaceutical Inc. | 0.20% | 7,596 | $320K | — |
Portfolio Sells Q4 2024
No earlier filing to compare with.
Portfolio Buys Q4 2024
No earlier filing to compare with.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 18 | $176.2M | ADMA, PALI, NRXP, FTH, TSHA |
| Q1 2026 | 20 | $134.9M | ADMA, PALI, PRAX, CLLS, ZLAB |
| Q4 2025 | 15 | $134.9M | ADMA, CLLS, PALI, TSHA, PRAX |
| Q3 2025 | 16 | $100.1M | ADMA, ZLAB, AKRO, CLLS, TSHA |
| Q2 2025 | 15 | $115.8M | ADMA, INSM, ZLAB, AKRO, CLLS |
| Q1 2025 | 17 | $115.1M | ADMA, INSM, ZLAB, AKRO, IOVA |
| Q4 2024 | 18 | $163.6M | INVESCO QQQ TR, ADMA, INSM, ZLAB, IOVA |